Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Apr 29 2010

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

In this complete response letter there are no requests for new pre-clinical or clinical trials. The sole issue raised in this letter concerns a deficiency of the manufacturing facility for this application. The manufacturer has responded to the FDA and continues to work with the FDA to resolve the matter. The facility only manufactures COLAZAL® Capsules and GIAZO™ Tablets for Salix.

Source:

Salix Pharmaceuticals, Ltd.,

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , ,

Comments (0)

Suggested Reading

New drug combination may improve treatment for rare nerve sheath tumors
Nitrite analysis in pharmaceuticals: monitoring a precursor to nitrosamine
Study identifies common skin bacterium as previously unknown culprit behind itch
Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer
Study finds no link between anxiety or depression and IVF outcomes in men
The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns
From Cells to Drugs: How Cell Painting is Transforming Drug Discovery
New understanding of lung cancer cells' 'memories' suggests novel treatment approach

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »
You might also like...
Drug combo safely decreases pancreatic cancer growth in mice